Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538).
Kumar
G N
GN
Department of Biotransformation, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Grabowski
B
B
Lee
R
R
Denissen
J F
JF
D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004790:Enzyme Induction; D004997:Ethinyl Estradiol / Q000378:metabolism; D005260:Female; D014453:Glucuronosyltransferase / Q000096:biosynthesis*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D009929:Organ Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D019438:Ritonavir / Q000494:pharmacology*
D017320:HIV Protease Inhibitors; D004997:Ethinyl Estradiol; D003577:Cytochrome P-450 Enzyme System; D014453:Glucuronosyltransferase; D019438:Ritonavir